High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer

Cell surface mannose 6-phosphate/insulin-like growth factor II receptors (M6P/IGF2R) bind and target exogenous insulin-like growth factor II (IGF2) to the prelysosomes where it is degraded. Loss of heterozygosity (LOH) for M6P/IGF2R is found in cancers, with mutational inactivation of the remaining allele. We exploited the normal allele-specific differential methylation of the M6P/IGF2R intron 2 CpG island to rapidly evaluate potential LOH in ovarian cancers, since every normal individual is informative. To this end, we developed a method for bisulfite modification of genomic DNA in 96-well format that allows for rapid methylation profiling. We identified ovarian cancers with M6P/IGF2R LOH, but unexpectedly also found frequent abnormal acquisition of methylation on the paternally inherited allele at intron 2. These results demonstrate the utility of our high-throughput method of bisulfite modification for analysis of large sample numbers. They further show that the methylation status of the intron 2 CpG island may be a useful indicator of LOH and biomarker of disease.

[1]  C. Polychronakos,et al.  The insulin-like growth factor-II receptor gene is associated with type 1 diabetes: evidence of a maternal effect. , 2004, The Journal of clinical endocrinology and metabolism.

[2]  A. Hoffman,et al.  Divergent evolution in M6P/IGF2R imprinting from the Jurassic to the Quaternary. , 2001, Human molecular genetics.

[3]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Barlow,et al.  The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus , 1991, Nature.

[5]  D. Barlow,et al.  Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. , 1993, Cell.

[6]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[7]  E. Mariman,et al.  The insulin–like growth factor type–2 receptor gene is imprinted in the mouse but not in humans , 1993, Nature Genetics.

[8]  R. Jirtle,et al.  Imprinted genes in liver carcinogenesis , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  C. Gicquel,et al.  Loss of heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor locus: a frequent but late event in adrenocortical tumorigenesis. , 2001, European journal of endocrinology.

[10]  D. Barlow,et al.  Conservation of a maternal-specific methylation signal at the human IGF2R locus. , 1995, Human molecular genetics.

[11]  Tomoyuki Masuda,et al.  M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan , 2002, Hepatology.

[12]  L. Shaffer,et al.  Epigenetic detection of human chromosome 14 uniparental disomy , 2003, Human mutation.

[13]  D. Barlow,et al.  Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal , 1993, Cell.

[14]  R. Bentley,et al.  M6P/IGF2 receptor: a candidate breast tumor suppressor gene. , 1996, Oncogene.

[15]  Christoph Grunau,et al.  Bisulfite genomic sequencing: systematic investigation of critical experimental parameters , 2001, Nucleic Acids Res..

[16]  M. Washington,et al.  M6P/IGF2R is mutated in squamous cell carcinoma of the lung , 2000, Oncogene.

[17]  M. West,et al.  Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers , 2005, Clinical Cancer Research.